Effectiveness of a collaborative diabetes screening campaign between community pharmacies and general practitioners |
| |
| Affiliation: | 1. Centre for Health Evaluation & Research/Infosaúde, National Association of Pharmacies (CEFAR/IS-ANF), Rua Marechal Saldanha 1, 1249-069 Lisbon, Portugal;2. Life and Health Sciences Research Institute (ICVS), School of Medicine, Campus de Gualtar, Universidade do Minho, 4710-057 Braga, Portugal;3. ICVS/3B''s-PT Government Associate Laboratory, Campus de Gualtar, Universidade do Minho, 4710-057 Braga, Portugal;1. Division of Hematology/Oncology, Boston Children''s Hospital, Boston, MA;2. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;3. Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA;4. ARUP Institute for Clinical and Experimental Pathology, ARUP Laboratories, Salt Lake City, UT;5. Department of Pathology, University of Utah, Salt Lake City, UT;6. Immunology Service, Department of Laboratory Medicine, Clinical Center, and Primary Immune Deficiency Clinic, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD;7. Departments of Pediatrics and Medicine, University of Utah, Salt Lake City, UT;1. Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran;2. Non-communicable Disease Research Center, Alborz University of Medical Sciences, Karaj, Islamic Republic of Iran;3. Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran;4. Evidence-Based Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran;5. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran;6. Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran |
| |
| Abstract: | AimTo evaluate the impact of a collaborative screening campaign on the prevalence of pre-diabetes and diabetes among the screened population.MethodsA Longitudinal, multicentre study was developed. The Finnish Diabetes Risk Score (FINDRISC) was applied to the eligible population in the participating community pharmacies. Individuals with a FINDRISC score ≥ 15, were eligible to measure their glycated haemoglobin (HbA1c) level at the community pharmacy. If HbA1c≥ 5.7%, participants were referred to a general practitioner (GP) appointment for potential diagnosis of Diabetes.ResultsOut of 909 screened subjects, 405 (44.6%) presented a FINDRISC score ≥ 15. Among the latter, 94 (23.4%) had HbA1c levels that made them eligible for GP referral, of which 35 (37.2%) completed the scheduled appointments. 24 participants were diagnosed with pre-diabetes, and 11 with diabetes. The prevalence was estimated at 2.5% (CI95% 1.6–3.8%) and 7.8% (CI95% 6.2–9.8%) for diabetes and pre-diabetes, respectively.ConclusionThis collaborative model has proved to be effective in the early detection of diabetes and pre-diabetes. Joint initiatives between health professionals can play a pivotal role in the prevention and diagnosis of diabetes, which may lead to a reduction on the burden to health system and society. |
| |
| Keywords: | Diabetes FINDRISC Prevention Early diagnosis Collaborative model Community Pharmacies |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
